AR048334A1 - Tetrahidrocarbazoles y sus derivados; metodos para su preparacion, composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento y prevencion de enfermedades moduladas por agonistas de los receptores hepaticos lxralfa y/o lxrbeta. - Google Patents

Tetrahidrocarbazoles y sus derivados; metodos para su preparacion, composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento y prevencion de enfermedades moduladas por agonistas de los receptores hepaticos lxralfa y/o lxrbeta.

Info

Publication number
AR048334A1
AR048334A1 ARP050101164A ARP050101164A AR048334A1 AR 048334 A1 AR048334 A1 AR 048334A1 AR P050101164 A ARP050101164 A AR P050101164A AR P050101164 A ARP050101164 A AR P050101164A AR 048334 A1 AR048334 A1 AR 048334A1
Authority
AR
Argentina
Prior art keywords
alkyl
group
halogen
heteroaryl
aryl
Prior art date
Application number
ARP050101164A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR048334A1 publication Critical patent/AR048334A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/70—[b]- or [c]-condensed containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/86—Carbazoles; Hydrogenated carbazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Tetrahidrocarbazoles y sus derivados, los compuestos son utiles para el tratamiento y profiláxis de enfermedades que son moduladas por agonistas LXRalfa y/o LXRbeta, indluyendo niveles incrementados de lípidos y colesterol, particuilarmente bajo colesterol-HDL, alto colesterol-LDL, enfermedades ateroscleroticas, diabetes, particularmente diabetes mellitus no-insulino dependiente, síndrome metabolico, dislipidemia, enfermedad de Alzheimer, sepsis, enfermedades inflamatorias tales como colitis, pancreatitis, colestasis/fibrosis del hígado, y enfermedades que tienen un componente inflamatorio tales como enfermedad de Alzheimer o funcion cognitiva deteriorada/mejorable. Reivindicacion 1: Compuestos de la formula (1) en donde n es un numero entero seleccionado de 0 a 3; R1 es independientemente seleccionado del grupo que consiste en halogeno, -CN, -NO2, -SO2Me, alquilo inferior, trifluorometoxilo, -OR11,m piperidinilo, pirrolidinilo, y -N(R11)(R11), en donde R11 es independientemente seleccionado de alquilo inferior y H; X1, X2, X3, y X4 son independientemente seleccionados de N y C, con la condicion de que no más de dos de X1, X2, X3, y X4 puedan ser N a la vez, y cuando dos de X1, X2, X3, y X4 son N, n es 0, 1 o 2; k es un numero entero de 0 a 1; R2 es H; R3 es H, alquilo, o halogeno; R4 es arilo, heteroarilo, alquilarilo o alquilheteroarilo, estando todos opcionalmente sustituidos con 1 a 5 sustituyentes seleccionados independientemente del grupo que contiene halogeno, alquilo, -OR41, alquinilo inferior, y NR42R43, en donde R41es alquilo inferior o -H, R42 y R43 independientemente de cada uno son H o alquilo, o NR42R43 es piperidinilo o pirrolidinilo, oR4 es alquilo; R5 es seleccionado del grupo que consiste en el grupo de formulas (2) estando dichos arilo y heteroarilo opcionalmente sustituidos en una o más posiciones con uno o más sustituyentes independinetemente seleccionados del grupo que consiste en H, halogeno, alquilo inferior y (CH2)vR53, en donde R51 se selecciona del grupo que consiste en H, alquilo, alquenilo inferior y alquilarilo, estando dicho alquilarilo opcionalmente sustituido en una o más posiciones con uno o más alquilos inferiores, -CN, halogeno, -COOR54, y - CH2OR54, en donde R54 es alquilo o -H; R52 es alquilo inferior o -H; R53 es H, alquiolo, cicloalquilo, COOR55, -N(R55)(R56), -CH2OH, -CN, CF3, -CONH2, -CH2OR55 o -CONR55R56, en donde R55 es independientemente seleccionado del grupo que consiste en alquilo, -H, -C(O)-arilo, -C(O)-alquilo, o -C(O)-heteroarilo, y R56 se selecciona el grupo que consiste en H, alquilo, C(O)CF3, -C(O)-arilo, -C(O)-alquilo, -C(O)-heteroarilo, alquilarilo y alquilheteroarilo, y en donde dicho arilo, heteroarilo, alquilarilo y alquil-heteroarilo son opcionalmente sustituidos en una o más posiciones con uno o más de alquilo, -CN, halogeno, -COOR57, y -CH2OR57, en donde R57 es alquilo inferior o -H, o R55 y R56 junto con el átomo al que están unidos forman un anillo; o R53 es arilo que puede opcionalmente estar sustituido con benciloxilo, carboxilo, alcoxilo inferior carbonilo, hidroxi-alquilo inferior, halogeno, carbamoilo, alquilo inferior-carbamoilo, dialquilo inferior-carbamoilo, m es un numero entero seleccionado de 0 a 2; v es un numero entero seleccionado de 0 a 4; y sales aceptables farmacéuticamente y/o ésteres aceptables farmacéuticamente de los mismos. Reivindicacion 35: Un proceso para la elaboracion de un compuesto de la formula (1) de acuerdo con cualquiera de las reivindicaciones 1 a 34, proceso que comprende losm pasos de hacer reaccionar un compuesto de la formula (3) en donde R2, R3, R4, R5 y k tienen el significado dado en cualquiera de las reivindicaciones 1 a 31, con un compuesto de la formula (4) en donde R1, n, X1, X2, X3, y X4 tienen el significado dado en cualquiera de las reivindicaciones 1 a 31, y transformar opcionalmente el compuesto de la formula (1) en uan sal farmacéuticamente aceptable y/o un éster farmacéutuicamente aceptable.
ARP050101164A 2004-03-26 2005-03-23 Tetrahidrocarbazoles y sus derivados; metodos para su preparacion, composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento y prevencion de enfermedades moduladas por agonistas de los receptores hepaticos lxralfa y/o lxrbeta. AR048334A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04101252 2004-03-26

Publications (1)

Publication Number Publication Date
AR048334A1 true AR048334A1 (es) 2006-04-19

Family

ID=34963176

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050101164A AR048334A1 (es) 2004-03-26 2005-03-23 Tetrahidrocarbazoles y sus derivados; metodos para su preparacion, composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento y prevencion de enfermedades moduladas por agonistas de los receptores hepaticos lxralfa y/o lxrbeta.

Country Status (27)

Country Link
US (2) US20050215577A1 (es)
EP (1) EP1732892B1 (es)
JP (1) JP4705630B2 (es)
KR (1) KR100803478B1 (es)
CN (1) CN1938273B (es)
AR (1) AR048334A1 (es)
AT (1) ATE408599T1 (es)
AU (1) AU2005225524B2 (es)
BR (1) BRPI0509275A (es)
CA (1) CA2560700A1 (es)
DE (1) DE602005009811D1 (es)
DK (1) DK1732892T3 (es)
ES (1) ES2314633T3 (es)
HK (1) HK1101911A1 (es)
HR (1) HRP20080651T3 (es)
IL (1) IL177704A (es)
MX (1) MXPA06010815A (es)
MY (1) MY140874A (es)
NO (1) NO20064820L (es)
NZ (1) NZ549396A (es)
PL (1) PL1732892T3 (es)
PT (1) PT1732892E (es)
RU (1) RU2382770C2 (es)
SI (1) SI1732892T1 (es)
TW (1) TW200539870A (es)
WO (1) WO2005092856A1 (es)
ZA (1) ZA200607491B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008065754A1 (fr) 2006-11-30 2008-06-05 Kowa Company, Ltd. Composé de carbinol substitué
FR2913886B1 (fr) 2007-03-22 2012-03-02 Guerbet Sa Utilisation de nanoparticules metalliques dans le diagnostique de la maladie d'alzheimer
EP2248811B1 (en) 2008-02-29 2012-11-14 Kowa Company, Ltd. 2-oxochromene derivative
WO2009115212A1 (en) * 2008-03-17 2009-09-24 F. Hoffmann-La Roche Ag Lxr ligand binding domain (lxr lbd) crystals
EP2264029A4 (en) * 2008-03-31 2011-08-24 Kowa Co 1,3-dihydroisobenzofuran DERIVATIVE
WO2009133692A1 (ja) 2008-04-30 2009-11-05 興和株式会社 キノリン化合物
BRPI0913212A2 (pt) * 2008-05-29 2019-09-24 Kowa Co composto de carbinol, remédio, regulador de lxr, composição farmacêutica, método para prevenir e/ou tratar doença, e, uso do derivado de carbinol ou sal do mesmo, ou seu solvato
FR2938537B1 (fr) 2008-11-14 2012-10-26 Sanofi Aventis Derives de carbamates d'alkyl-heterocycles, leur preparation et leur application en therapeutique.
NZ595910A (en) * 2009-04-29 2013-06-28 Kowa Co Carbinol compound having heterocyclic linker
SI2623499T1 (sl) 2010-10-01 2015-10-30 Taisho Pharmaceutical Co., Ltd. Derivat 1,2,4-triazolona
DE102011055815A1 (de) 2011-11-29 2013-05-29 Aicuris Gmbh & Co. Kg Carboxamid-substituierte Heteroaryl-Pyrazole und ihre Verwendung
WO2013170186A1 (en) * 2012-05-11 2013-11-14 Reset Therapeutics, Inc. Carbazole-containing sulfonamides as cryptochrome modulators
DE102012016908A1 (de) 2012-08-17 2014-02-20 Aicuris Gmbh & Co. Kg Tris-(Hetero)Aryl-Pyrazole und ihre Verwendung
BR112015023267B1 (pt) 2013-03-15 2023-01-31 Epigen Biosciences, Inc Composto, e medicamento para tratar um indivíduo com doença ou condição lisofosfatídica dependente de ácido
CN103910659B (zh) * 2013-11-04 2016-05-11 迈克斯(如东)化工有限公司 2-硝基-4-甲磺酰基苯甲酸的精制方法及其中间体
EP3080099B1 (en) 2013-12-13 2018-04-11 F.Hoffmann-La Roche Ag Inhibitors of bruton's tyrosine kinase
WO2015106164A1 (en) 2014-01-10 2015-07-16 Rgenix, Inc. Lxr agonists and uses thereof
TWI690521B (zh) 2014-04-07 2020-04-11 美商同步製藥公司 作為隱花色素調節劑之含有咔唑之醯胺類、胺基甲酸酯類及脲類
WO2017023916A1 (en) * 2015-08-05 2017-02-09 Georgetown University Small molecule androgen receptor inhibitors and methods of use thereof
CN109069461A (zh) 2016-01-11 2018-12-21 洛克菲勒大学 与髓源性抑制细胞相关的病症的治疗方法
EP3713575A4 (en) 2017-11-21 2021-08-25 Rgenix, Inc. POLYMORPHS AND THEIR USES
US20200085810A1 (en) 2018-07-26 2020-03-19 Hoffmann-La Roche Inc. Compounds for use in treating kidney disorders
CA3161274A1 (en) 2019-12-13 2021-06-17 Stephen Wald Metal salts and uses thereof
CN111518002B (zh) * 2020-05-21 2022-06-21 南京林业大学 一种硫醚类化合物及其制备方法、医药中间体及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003090746A1 (en) * 2002-04-23 2003-11-06 Chugai Seiyaku Kabushiki Kaisha 1,3-thiazoles as lxr modulators in the treatment of cardiovascular diseases
WO2003090732A1 (en) * 2002-04-23 2003-11-06 Chugai Seiyaku Kabushiki Kaisha Lxr modulators for the treatment of cardiovascular diseases
MXPA04011690A (es) * 2002-05-24 2005-03-31 Pharmacia Corp Moduladores de receptor x de higado de sulfona.
TWI329111B (en) * 2002-05-24 2010-08-21 X Ceptor Therapeutics Inc Azepinoindole and pyridoindole derivatives as pharmaceutical agents
AU2003256655A1 (en) * 2002-07-25 2004-02-16 Merck And Co., Inc. Therapeutic compounds for treating dyslipidemic conditions

Also Published As

Publication number Publication date
US20100216833A1 (en) 2010-08-26
RU2006137655A (ru) 2008-05-10
DK1732892T3 (da) 2009-01-05
SI1732892T1 (sl) 2009-02-28
KR100803478B1 (ko) 2008-02-14
JP2007530480A (ja) 2007-11-01
MXPA06010815A (es) 2006-12-15
WO2005092856A1 (en) 2005-10-06
US7906546B2 (en) 2011-03-15
PL1732892T3 (pl) 2009-03-31
NZ549396A (en) 2010-04-30
JP4705630B2 (ja) 2011-06-22
EP1732892B1 (en) 2008-09-17
ZA200607491B (en) 2008-06-25
ATE408599T1 (de) 2008-10-15
CN1938273B (zh) 2011-12-14
WO2005092856A8 (en) 2006-12-21
MY140874A (en) 2010-01-29
PT1732892E (pt) 2008-12-22
US20050215577A1 (en) 2005-09-29
RU2382770C2 (ru) 2010-02-27
NO20064820L (no) 2006-10-24
IL177704A0 (en) 2006-12-31
IL177704A (en) 2011-09-27
KR20060124780A (ko) 2006-12-05
AU2005225524A1 (en) 2005-10-06
HK1101911A1 (en) 2007-11-02
CA2560700A1 (en) 2005-10-06
EP1732892A1 (en) 2006-12-20
TW200539870A (en) 2005-12-16
CN1938273A (zh) 2007-03-28
BRPI0509275A (pt) 2007-09-04
DE602005009811D1 (de) 2008-10-30
ES2314633T3 (es) 2009-03-16
HRP20080651T3 (en) 2009-01-31
AU2005225524B2 (en) 2007-11-22

Similar Documents

Publication Publication Date Title
AR048334A1 (es) Tetrahidrocarbazoles y sus derivados; metodos para su preparacion, composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento y prevencion de enfermedades moduladas por agonistas de los receptores hepaticos lxralfa y/o lxrbeta.
ES2655669T3 (es) Derivados de piridinona y pirimidinona como inhibidores del factor XIa
JP6213564B2 (ja) キノリン誘導体
HRP20230052T1 (hr) Spojevi derivata 1,3,4-oksadiazol sulfonamida kao inhibitori histonske deacetilaze 6, i farmaceutski pripravak koji ih sadrži
HRP20220003T1 (hr) Spojevi derivata 1,3,4-oksadiazola kao inhibitori histonske deacetilaze 6, i farmaceutski pripravak koji ih sadrži
AR058901A1 (es) Compuestos derivados de hidantoina, utiles para el tratamiento de trastornos inflamatorios y composicion farmaceutica que los comprende
HRP20151425T1 (hr) Inhibitori indazola wnt signalnog puta i njihove terapeutske uporabe
EA201170193A1 (ru) Новые содержащие серу липиды для применения в качестве пищевой добавки или в качестве лекарственного средства
SI2303270T1 (en) Acylamino-substituted fused cyclopentanecarboxylic acid derivatives and their use as pharmaceutical products
EA201171371A1 (ru) Полиненасыщенные жирные кислоты для лечения заболеваний, связанных с сердечно-сосудистыми, метаболическими и воспалительными заболеваниями
AR048537A1 (es) Derivados de nucleosidos para tratar infecciones por virus de hepatitis c.
RU2011108024A (ru) 3-азабицикло(3.1.0) гексильные производные в качестве модуляторов метаботропных глутаматных рецепторов
AR071857A1 (es) Derivados de indazol sustituidos con fenilo y benzodioxinilo, una composicion farmaceutica que los comprende y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por el receptor de glucocorticoides.
MA35750B1 (fr) Dérivés de nucléoside substitué 2',4'-difluoro-2'-méthyle en tant qu'inhibiteurs de la réplication de l'arn du vhc (virus de l'hépatite c)
HRP20161237T1 (hr) Antimalarijski agensi
AR039219A1 (es) Compuestos imidazo-sustituidos
AR091857A1 (es) INHIBIDORES DE CISTATIONIN-g-LIASA (CSE)
AR060609A1 (es) Compuestos inhibidores de proteinquinasas c-fms.
AR035612A1 (es) 4-(piperidin-4-ilmetil)benzamidas, o sus sales, esteres o solvatos, composiciones farmaceuticas que los comprenden, usos de los mismos para preparar medicamentos, y un kit para utilizar en el tratamiento de una enfermedad cognitiva o neurodegenerativa
RU2015104969A (ru) Производные пиридинона в качестве ингибиторов трансглутаминазы тканей
JP2016511753A5 (es)
RU2017117559A (ru) Бензопроизводные с шестичленным кольцом в качестве ингибитора dpp-4 и их применение
AR110241A1 (es) Ácidos indanilaminopiridil-ciclopropano-carboxílicos, composiciones farmacéuticas y usos de los mismos
AR077534A1 (es) Derivados de isoxazol, un proceso para su obtencion, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades relacionadas con el receptor gaba aalfa5
AR040724A1 (es) Compuesto de imidazopiridina, composicion farmaceutica que lo comprende y su uso para la fabricacion de un medicamento

Legal Events

Date Code Title Description
FG Grant, registration